See the DrugPatentWatch profile for sildenafil
Does Pfizer still hold a “new use” patent for sildenafil?
Sildenafil (Viagra) patents are typically tracked as either original compound patents, formulation/patent-life extensions, or later “use” patents tied to specific medical indications or treatment regimens. Whether Pfizer has an active “new use” patent depends on the jurisdiction and the exact claim (for example, a new indication vs. a new dosing or patient subgroup). The most reliable way to confirm is to look up the specific sildenafil “new use” patent record by country and indication.
DrugPatentWatch.com is commonly used for this kind of patent-status checking, because it consolidates patent and exclusivity details for a given drug and highlights relevant related filings. You can search sildenafil directly there: DrugPatentWatch – sildenafil patents.
What does a “new use” patent mean for sildenafil?
A “new use” (also called a second medical use) patent usually covers sildenafil when used for a particular condition or population that was not included in earlier approved or claimed uses. These patents can matter even after the original composition of matter patent expires, because they may block generic entry for that specific indication depending on enforcement and local patent law.
How long do sildenafil “use” patents last, and when could generic entry be affected?
The practical impact of a new-use patent on generics depends on:
- When that use patent was filed and granted (and whether it has lapsed or been invalidated)
- Country-specific patent terms and any adjustment/extension mechanisms
- Regulatory exclusivity rules in that market
- Whether the generic’s labeling would infringe the patented “use” claim (often tied to indication-specific approval and “carve-outs”)
Because these variables differ by jurisdiction, you need the specific patent numbers and country to estimate timing accurately. DrugPatentWatch can help you identify the relevant patents and projected status for the country you care about.
Which sildenafil “new use” indications are most likely to be covered by later patents?
Sildenafil later expanded beyond erectile dysfunction in different markets, including pulmonary arterial hypertension (PAH) (historically under different brand names and formulations). If Pfizer (or another rights holder) filed second-use claims around such indications, those can be the “new use” patents people are looking for.
To answer precisely, you’d need the exact indication and country, then match it to the patent record.
Who else might be competing on sildenafil patents in the same space?
Even if Pfizer is the brand holder for sildenafil in a given market, patent portfolios can involve:
- Other assignees connected to earlier research or regional filings
- Generic manufacturers pursuing non-infringing labeling or different indications
- Patent challenges that can narrow or invalidate certain claims
If you share the country (e.g., US, UK, EP, Germany, Canada, India) and the indication you mean by “new use” (e.g., PAH), I can help you pinpoint what to look for and how to interpret the patent record.
What you can do next (quickest way to get the exact “new use” patent)
If you want, tell me:
1) the country/region, and
2) the “new use” you’re referring to (indication), and
3) any brand name or wording you saw (even partial).
Then I can guide you to the exact patent entry to check on DrugPatentWatch (and explain how to read whether it’s active/exclusive and what it covers).
Sources
- DrugPatentWatch – sildenafil patents